Impact of Patent Expirations and Biosimilar Growth
The expiration of patents for several blockbuster erythropoietin biologics has transformed the Erythropoietin Drugs Market. Biosimilars have entered with aggressive pricing, making treatment more accessible to patients worldwide.
This shift is particularly pronounced in cost-sensitive regions such as Latin America and Asia-Pacific, where governments are integrating biosimilars into public health programs.
While brand loyalty keeps a segment of prescribers aligned with originator drugs, the growing trust in biosimilars—backed by clinical data—is eroding the dominance of branded biologics. This competitive evolution is expected to accelerate over the next decade.
3 Views